Cipla sees no major impact on biz from Donald Trump admin's decision to pause foreign aid: Umang Vohra

Cipla, a drugmaker involved in supplying HIV medications through US-supported programmes, anticipates minimal impact from the Trump administration's decision to pause foreign aid, including PEPFAR. The company's sales from PEPFAR are below $5 million, with low margins. Cipla's reduced dependence on tenders and significant US investments have de-risked its business model, ensuring stability.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yIsteB2
via IFTTT